Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Ad-SOCS2 infection alleviated STZ-induced renal injury and pathological changes and inhibited STZ-induced IL-6, IL-1β and MCP-1 generation and activation of the TLR4/NF-κB pathway in DN rats.
|
29207635 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although previous studies have demonstrated the importance of MCP-1 in the pathogenesis of diabetic nephropathy (DN) in terms of inflammation, the role of MCP-1 and its receptor (C-C chemokine receptor 2; CCR2) in extracellular matrix (ECM) accumulation under diabetic conditions has been largely unexplored.
|
18579703 |
2008 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Associations of baseline uEGF, uMCP-1 and uEGF/MCP-1 with kidney outcome were assessed in a longitudinal cohort (n = 208) of advanced-stage DKD.
|
30357416 |
2020 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cilostazol demonstrated renoprotective effects in patients with diabetic nephropathy by reducing serum soluble adhesion molecule-1 and monocyte chemoattractant protein-1.
|
28293857 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
RGD |
Collectively, these results suggest that LAB has beneficial effects on the diabetic nephropathy in OLETF rats by decreasing blood pressure, oxidative stress, and MCP-1 expression.
|
18031723 |
2008 |
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared to the normal control, LPS and IL-15 down-regulate monocytic VDR expression in T2DM patients and DN uremic patients, whilst with cytoskeletal rearrangement, they up-regulate p-STAT5 expression as well as IL-6 and MCP-1 activity.
|
22322482 |
2012 |
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with DN group, the levels of TNF-α, IL-6, IL-1β, and MCP-1 were decreased in the PS-H group (p < 0.05).
|
31117104 |
2019 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conversely, levels of interleukin (IL)-1, IL-6, tumour necrosis factor-α and monocyte chemotactic protein-1 were higher in the DN group than in the control group.
|
29999450 |
2019 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, we detected the MCP-1-positive cells in the interstitium of diabetic nephropathy via both immunohistochemical and in situ hybridization analyses.
|
11012884 |
2000 |
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hematoxylin and eosin staining indicated that the infiltration of macrophages was significantly decreased in the high-dose TS group when compared with the DN group (P<0.01). mRNA and protein expression levels of MCP-1 and MIF in the high-dose TS group were significantly decreased when compared with the DN group (P<0.05).
|
29434819 |
2018 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the relationship between miR-374a and MCP-1 in DN is unknown.
|
30147653 |
2018 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, correlations between urinary monocyte chemoattractant protein-1 and glycemic and inflammatory marker levels revealed the role of hyperglycemia and chronic inflammation in the pathogenesis of diabetic kidney disease.
|
31250339 |
2019 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, MCP-1 AA genotype and A allele may play a specific role(s) in determining diabetic susceptibility, but do not seem to be important in the clinical manifestations of DN.
|
20960176 |
2010 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
RGD |
In conclusion, Col prevents not only inflammatory cell infiltration via inhibition of enhanced MCP-1 and ICAM-1 expression but also ECM accumulation in DN.
|
19369290 |
2009 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
CTD_human |
In conclusion, our study demonstrates that MCP-1-mediated macrophage accumulation and activation plays a critical role in the development of STZ-induced mouse diabetic nephropathy.
|
16374426 |
2006 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
It has been proposed that locally produced MCP-1 may be involved in the development of diabetic nephropathy (DN).
|
15280531 |
2004 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies reveal that pathways relevant to inflammation participate in the pathogenesis of DN, however, consumption of vitamin D-related products negatively regulates inflammatory response at multiple levels, indicated by inhibiting macrophage infiltration, nuclear factor-kappa B (NF-κB) activation, and production of such inflammatory mediators as transforming growth factor-β(TGF-β), monocyte chemoattractant protein 1(MCP-1), and regulated upon activation normal T cell expressed and secreted protein(RANTES).
|
30287151 |
2019 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we investigated in vivo if glomerular CCR2 expression is altered in kidney biopsies from patients with diabetic nephropathy and whether lack of MCP-1 affects proteinuria and expression of nephrin in experimental diabetes.
|
19587356 |
2009 |
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Most of these eleven genetic variants were involved in GPCR signaling and receptor binding pathways whereas four were involved in chronic kidney failure. rs833061 [OR 2.08 (95% CI 1.63-2.66)] in the VEGFA gene and rs3917887 [OR 2.04 (95% CI 1.64-2.54)] in the CCL2 gene showed the most significant association with the risk of diabetic nephropathy.
|
25280384 |
2014 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our in vitro and in vivo findings indicate a role for the MCP-1/CCR2 system in fibronectin deposition in the diabetic glomerulus, providing a new therapeutic target for diabetic nephropathy.
|
17968528 |
2008 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
LHGDN |
Our in vitro and in vivo findings indicate a role for the MCP-1/CCR2 system in fibronectin deposition in the diabetic glomerulus, providing a new therapeutic target for diabetic nephropathy.
|
17968528 |
2008 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated the importance of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of diabetic nephropathy in terms of inflammation, but the direct role of the MCP-1/CCR2 system on podocyte apoptosis under diabetic conditions has never been explored.
|
22006533 |
2012 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent evidence demonstrates that this anti-hyperglycaemic drug exerts renal protective effects, yet the mechanisms remain poorly understood. monocyte chemoattractant protein 1 (MCP-1) has been recognized as a key mediator of renal fibrosis in chronic kidney diseases, including diabetic nephropathy.
|
29934960 |
2019 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
|
28837800 |
2017 |
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The activation of TLRs stimulates the expression of several inflammatory cytokines and chemokines such as CCL2 and tumor necrosis factor (TNF)-α, which are associated with the progression of diabetic nephropathy.
|
28933050 |
2017 |